Song Eun Mi, Yang Suk-Kyun
Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea.
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Intest Res. 2022 Oct;20(4):418-430. doi: 10.5217/ir.2021.00104. Epub 2021 Dec 2.
Over the past decades, there has been a rapid increase in the incidence and prevalence of inflammatory bowel disease (IBD) in Asia. The natural history of IBD in Asian patients could be different from that in Western patients due to variations in disease phenotypes and genotypes as well as the healthcare environment between the 2 populations. To adequately cope with this disease, it is important to fully understand the potential differences in its natural history among different populations. In this review, we evaluated the differences in the clinical course of IBD between Asian and Western patients with regards to phenotypic progression, hospitalization, major surgery, risk of colorectal cancer, and mortality, mainly based on the results of population-based studies. The findings of our narrative review suggest that the clinical course of Asian patients with IBD, especially ulcerative colitis, is better than that of Western patients, as indicated by the lower rates of major surgery and hospitalization. In addition, similar to Western patients, the clinical course of Asian patients with IBD has been improving as evidenced by the decreasing rates of disease behavior progression (in Crohn's disease), hospitalization, and major surgery.
在过去几十年中,亚洲炎症性肠病(IBD)的发病率和患病率迅速上升。由于疾病表型和基因型的差异以及这两个人群之间的医疗环境不同,亚洲患者IBD的自然史可能与西方患者不同。为了充分应对这种疾病,全面了解不同人群中其自然史的潜在差异非常重要。在这篇综述中,我们主要基于基于人群的研究结果,评估了亚洲和西方IBD患者在表型进展、住院、大手术、结直肠癌风险和死亡率方面临床过程的差异。我们叙述性综述的结果表明,亚洲IBD患者,尤其是溃疡性结肠炎患者的临床过程优于西方患者,这体现在大手术和住院率较低。此外,与西方患者类似,亚洲IBD患者的临床过程也在改善,这表现为疾病行为进展(克罗恩病)、住院和大手术的发生率下降。